Deqing, China, June 6, 2014 / B3C newswire / - Shuwen Biotech Co. Ltd., a diagnostic company focused on licensing, developing and commercializing diagnostic kits and services for unmet clinical needs in China, has announced today that it has formed an alliance with the Canada-based DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) to commercialize the Previstage™ GCC colorectal cancer staging test in China.
Under the exclusive license and collaboration agreement, DiagnoCure has granted Shuwen Biotech an exclusive license to commercialize the Previstage™ GCC colorectal cancer staging test in the Greater China Region (China, Hong Kong, and Taiwan). Shuwen Biotech will conduct clinical trials in China on an IVD kit format of the Previstage™ test, and obtain a regulatory approval from the Chinese FDA for the kit. Shuwen Biotech will manufacture the IVD kit in its own manufacturing facilities and market the kit to major Chinese hospitals. In addition, Shuwen Biotech will also offer the Previstage™ testing service from its own clinical reference lab.
“Shuwen Biotech is a leading molecular diagnostic company in China led by its Chairman and CEO Jay Z. Zhang, a diagnostic industry veteran, who was formerly a senior vice president at Myriad Genetics. Collaborating with Jay and his team will undoubtedly create value for both corporations and most importantly help colon cancer patients receive the most appropriate treatment,” commented Dr. Yves Fradet, President and Chief Medical Officer of DiagnoCure.
“The ability to collaborate with DiagnoCure and to market Previstage™ GCC in the Greater China Region provides Shuwen with an exciting opportunity. We strongly believe in the benefits of Previstage™ GCC to help in staging and better control of colorectal cancer, a condition afflicting unfortunately a growing number of patients in China,” said Mr. Jay Z. Zhang.
About Shuwen Biotech Co., LTD
Based in China, Shuwen Biotech is a diagnostic company providing China’s physicians and their patients with the most innovative diagnostic products and services to meet the growing need for improved prediction, prevention, diagnosis, prognosis, and treatment of diseases. The company is engaged in licensing, developing, marketing and distributing innovative diagnostic products and services for disease diagnosis and personalized medicine.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.
Jay Z. Zhang
Shuwen Biotech Co., Ltd.